Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: all 157 studies

Page 1 of 2. Open to participants first (66), then studies with results posted, then the rest; newest registration first within each.

• Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)AvailableNCT07862465
• A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesEnrolling by invitationNCT07784309Phase 1
• Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/LymphomaNot yet recruitingNCT07774377Phase 3
• A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/LymphomaNot yet recruitingNCT07678307Phase 1/2
• Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingNCT07636564Phase 2
• Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation for T-Lymphoblastic Leukemia/Lymphoma in First Complete RemissionNot yet recruitingNCT07577531
• Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Phase 1/2
• Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaRecruitingNCT07513129Phase 1
• Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALLNot yet recruitingNCT07476027Early Phase 1
• Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).RecruitingNCT07471789Phase 1/2
• Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingNCT07388563Phase 1
• Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 2
• Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) PatientsRecruitingNCT07313592
• Anti-CCR9 CAR T Cells for T Cell Leukaemia/LymphomaRecruitingNCT07300683Phase 1
• Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell TransplantationRecruitingNCT07256210Phase 2
• Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T CellsRecruitingNCT07220993Phase 1
• HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesNot yet recruitingNCT07175415Phase 1/2
• Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingNCT07159620Phase 2
• A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/LymphomaRecruitingNCT07075328Phase 1/2
• Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Not yet recruitingNCT07072585Phase 2/3
• A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte MalignanciesRecruitingNCT07070323Phase 1/2
• Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"RecruitingNCT07021677Phase 2
• Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid MutationsRecruitingNCT07012447Phase 2
• Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or LymphomaRecruitingNCT06934382Phase 1
• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
• Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHLRecruitingNCT06874946Phase 1/2
• Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingNCT06855810Phase 2/3
• A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1RecruitingNCT06698003Phase 2
• Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse PreventionRecruitingNCT06686108Phase 2
• Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic LeukemiaRecruitingNCT06648889Phase 2
• Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALLRecruitingNCT06633354Early Phase 1
• Novel Therapeutic Approach for Human T-cell MalignanciesRecruitingNCT06600568
• BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.RecruitingNCT06598722Phase 2
• A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)RecruitingNCT06561074Phase 2
• A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)RecruitingNCT06514794Phase 2
• Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T CellsRecruitingNCT06420076Phase 1/2
• Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 2
• Haplo-cord HCT vs. Haplo-HCT for T-ALL PatientsRecruitingNCT06381817Phase 3
• CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell MalignanciesRecruitingNCT06316856Phase 1/2
• Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell MalignanciesRecruitingNCT06316427Phase 1/2
• CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LLRecruitingNCT06064903Phase 1/2
• Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaRecruitingNCT05996185Phase 2
• Universal 4SCAR7U Targeting CD7-positive MalignanciesNot yet recruitingNCT05995028Phase 1
• A Registry for People With T-cell LymphomaRecruitingNCT05978141
• HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
• HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
• Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LLRecruitingNCT05679895Phase 1
• HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05658640Phase 1/2
• Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBLRecruitingNCT05626400Not applicable
• Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBLRecruitingNCT05598593Phase 2
• CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic LeukemiaRecruitingNCT05596266Phase 1
• A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007Enrolling by invitationNCT05509855
• Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL PatientsRecruitingNCT05376111Phase 2
• Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLRecruitingNCT05289687Phase 2
• Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
• Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & LymphomaRecruitingNCT04972942Phase 1
• Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/LymphomaRecruitingNCT04848064Phase 1
• Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALLRecruitingNCT04582487Not applicable
• CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)RecruitingNCT04318678Phase 1
• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingNCT04301076Phase 1
• Multi-CAR T Cell Therapy Targeting CD7-positive MalignanciesNot yet recruitingNCT04033302Phase 1/2
• Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 AntigenRecruitingNCT03081910Phase 1
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentRecruitingNCT01087333
• Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingNCT00501826Phase 2
• Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT05032183Phase 1/2Results posted
• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruitingNCT04703192Phase 2Results posted
• Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT03504644Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT03384654Phase 2Results posted
• BV-CHEP Chemotherapy for Adult T-cell Leukemia or LymphomaCompletedNCT03264131Phase 2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaActive, not recruitingNCT03113500Phase 2Results posted
• Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaTerminatedNCT02999633Phase 2Results posted
• Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT02767934Phase 2Results posted
• BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic LymphomaTerminatedNCT02763384Phase 2Results posted
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 2Results posted
• Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or LymphomaTerminatedNCT02518750Phase 2Results posted
• A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBLCompletedNCT02518113Phase 1/2Results posted
• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02484430Phase 2Results posted
• Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic LymphomaActive, not recruitingNCT02112916Phase 3Results posted
• A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALLTerminatedNCT01483690Phase 1/2Results posted
• EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01186328Phase 1Results posted
• Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LLTerminatedNCT00981799Phase 1/2Results posted
• Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT00792948Phase 2Results posted
• Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00557193Phase 3Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT00408005Phase 3Results posted
• Campath-1H for Treating Adult T-Cell Leukemia/LymphomaCompletedNCT00061048Phase 2Results posted
• Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT07585734Phase 1/2
• PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALLActive, not recruitingNCT07541755Phase 3
• A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell LymphomaSuspendedNCT06761677Phase 1/2
• Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaSuspendedNCT06738368Phase 2
• Daratumumab in VHR T-ALL Treated According to the ALL National Treatment ProgramActive, not recruitingNCT06253637Phase 2
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnNCT06210750Phase 2
• A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruitingNCT06035497Phase 1/2
• A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ LymphomaWithdrawnNCT05909527Phase 1/2
• A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)Active, not recruitingNCT05885464Phase 1/2
• Registry of Relapsed/Refractory T-cell Acute Lymphoblastic LeukemiaStatus unknownNCT05832125
• Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaActive, not recruitingNCT05602194Phase 3
• STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWithdrawnNCT05519527Phase 1

← Precursor T-Cell Lymphoblastic Leukemia-Lymphoma overview